Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFOX vs mFOLFIRI vs FOLFPTX in Advanced Gastric Cancer
NCT03045770Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Feb 2017
- Primary completion
- Dec 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Randomised, open-label trial of oxaliplatin, irinotecan and paclitaxel in gastric cancer (GC) and adenocarcinoma of the esophagogastric junction (AEG) (3 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: Progression-Free Survival at 24 months and Adverse Event at 35 months. Status: unknown.
02
Drugs
oxaliplatinirinotecanpaclitaxel
03
Conditions
gastric cancer (GC)adenocarcinoma of the esophagogastric junction (AEG)
Beyond the preview
Go deeper on NCT03045770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03045770.